MSD’s Q3 2022 earnings report
October 27, 2022
MSD’s Q3 2022 results reflect sustained strong business momentum across key growth drivers as well as investment and progress in the pipeline. The company announced Q3 worldwide sales of $15 billion, an increase of 14% from Q3 2021.
“We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver meaningful value for patients — which in turn provides value for our shareholders,” said Robert M. Davis, chief executive officer and president, MSD. “Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers. Inspired by our purpose of saving and improving lives around the world, I am confident we are well-positioned to continue to deliver strong operational performance.”
MSD anticipates full-year 2022 worldwide sales to be between $58.5 billion and $59 billion.
Take a look at the infographic below for more details.